Based on the data provided, Argenx SE (ARGX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with significant upside potential, a bullish technical setup, and positive catalysts such as upcoming Phase 3 data for Vyvgart and ALKIVIA studies. While there are no immediate trading signals or recent news, the overall sentiment and growth prospects make it a compelling long-term investment.
The technical indicators suggest a bullish trend. The MACD is above 0 and positively contracting, RSI is neutral at 52.622, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level (880.751), with key resistance at 905.963 and support at 855.539.

Strong analyst ratings with multiple price target increases, including Wells Fargo's target of $1,291, indicating significant upside potential.
Upcoming Phase 3 data for Vyvgart and ALKIVIA studies in Q3 2026, which could act as a major catalyst.
Durable growth in Vyvgart's revenue, with projections exceeding $6B in FY26.
Slightly bearish sentiment in options trading with a higher put-call volume ratio.
No recent news or significant insider or hedge fund activity to provide additional momentum.
No financial data available for analysis.
Analysts are overwhelmingly positive on the stock, with multiple buy and overweight ratings. Recent price target increases range from $1,016 to $1,291, reflecting confidence in the company's growth trajectory and upcoming catalysts.